about
Synthesis, structure and inhibitory activity of a stereoisomer of oseltamivir carboxylateSelective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampusCyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studiesAmino Acid Derivatives as Palmitoylethanolamide Prodrugs: Synthesis, In Vitro Metabolism and In Vivo Plasma Profile in RatsPromotion of non-rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligandNovel N-Acetyl Bioisosteres of Melatonin: Melatonergic Receptor Pharmacology, Physicochemical Studies, and Phenotypic Assessment of Their Neurogenic Potential.Identification of a bioactive impurity in a commercial sample of 6-methyl-2-p-tolylaminobenzo[d][1,3]oxazin-4-one (URB754).Synthesis and structure-activity relationships of N-(2-oxo-3-oxetanyl)amides as N-acylethanolamine-hydrolyzing acid amidase inhibitors.Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors.MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential.Therapeutic uses of melatonin and melatonin derivatives: a patent review (2012 - 2014).Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands.Structure-based virtual screening of MT2 melatonin receptor: influence of template choice and structural refinement.N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands.Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders.UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations.ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors.URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices.Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates.Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation.Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.Recent advances in the development of melatonin MT(1) and MT(2) receptor agonists.Melatonin receptor agonists: new options for insomnia and depression treatment.Epidermal growth factor receptor irreversible inhibitors: chemical exploration of the cysteine-trap portion.Insights in the mechanism of action and inhibition of N-acylethanolamine acid amidase by means of computational methods.Pharmacokinetic and pharmacodynamic evaluation of ramelteon : an insomnia therapy.Synthesis and structure-activity relationships of amino acid conjugates of cholanic acid as antagonists of the EphA2 receptor.Metadynamics for Perspective Drug Design: Computationally Driven Synthesis of New Protein-Protein Interaction Inhibitors Targeting the EphA2 Receptor.Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors.Synthesis and characterization of new bivalent agents as melatonin- and histamine H3-ligands.Irreversible inhibition of epidermal growth factor receptor activity by 3-aminopropanamides.Dibasic biphenyl H3 receptor antagonists: Steric tolerance for a lipophilic side chain.MT1-selective melatonin receptor ligands: synthesis, pharmacological evaluation, and molecular dynamics investigation of N-{[(3-O-substituted)anilino]alkyl}amides.Toward the definition of stereochemical requirements for MT2-selective antagonists and partial agonists by studying 4-phenyl-2-propionamidotetralin derivatives.Reassessing the melatonin pharmacophore--enantiomeric resolution, pharmacological activity, structure analysis, and molecular modeling of a constrained chiral melatonin analogue.Bivalent ligand approach on N-{2-[(3-methoxyphenyl)methylamino]ethyl}acetamide: synthesis, binding affinity and intrinsic activity for MT(1) and MT(2) melatonin receptors.Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models.Synthesis, enantiomeric resolution, and structure-activity relationship study of a series of 10,11-dihydro-5H-dibenzo[a,d]cycloheptene MT2 receptor antagonists.2-N-acylaminoalkylindoles: design and quantitative structure-activity relationship studies leading to MT2-selective melatonin antagonists.2-[N-Acylamino(C1-C3)alkyl]indoles as MT1 melatonin receptor partial agonists, antagonists, and putative inverse agonists.
P50
Q27688897-BB6118B9-7AE0-45B9-9562-EA85265D949BQ28268567-1FFA0D5D-1C79-46D4-913E-340E8C655E62Q28285285-D9A23AED-401C-4F47-A6C1-B0CF1A1591FEQ28548007-2AF01352-054E-46F3-9391-3C1F245099DAQ28567937-FC9CBF4F-008F-4BEF-9B5B-6C43AA2BD521Q30961259-A5505C1A-7F13-4F73-A11E-38ED0232E053Q33304352-962D001B-655B-4049-B584-C4FBDC0A5470Q34101852-9ED50CF6-B36B-45BC-9886-DA77D9F7202FQ34200866-EB87B32B-0C8F-4E39-AECE-DFB8F75E37DDQ34384945-18698E4F-950B-401A-99F8-FF306E09C0E2Q34457651-3FA26650-B3D0-49D0-9F22-E9868A879469Q34588133-07CF330E-FDD9-467F-94A5-2B2B4511201DQ34642224-FCAEC3D0-481B-49F1-8AD5-D3A5A4D40035Q34720409-03A7A622-D2D2-4EB4-9DAD-9DCF67E6FCC7Q34803259-00493A62-D620-4866-970E-6E8DC51AE9FFQ34953306-55B060A0-C847-463C-82A8-A575571632BAQ35261315-94783374-B728-4486-80D1-1C0B23E650F4Q36427265-07A9478E-EB19-4BCC-915C-BE70688AC0BAQ37098652-D68F9F32-D824-4295-B32D-D04ABC5A8801Q37469677-5BA2FCBB-0C5A-49E3-909E-A0BF42E99055Q37635711-6AC947D0-79F5-40F9-857B-9523ABBC2934Q37763715-A26D831E-95CA-4216-B3F5-EAD682A93318Q37873581-EC517953-2E46-4B74-A8F0-DE60A7FF0666Q37921335-CF4F4A38-E111-4DEA-8C84-044AA60CD042Q38274600-345072BF-3B85-42BF-8D8E-1FAD7E1A1843Q38467876-A0B71785-9B56-4C44-B1F8-C1A07F0EC3ABQ39072727-B3AA8AAF-66E0-425D-A6EB-AFD11707833AQ39074330-2A4A3521-7268-440A-B47F-6608904BAB4AQ39103358-A76B042C-0924-4704-B5B5-6A7A5901D727Q39128977-C65282F5-7ADA-486D-9A2F-B09AB883D7BFQ39405800-8C755DD4-FDC4-4AB5-8ABB-C7C986618C3EQ39417068-386FCFD4-7E5C-48D5-B1E0-9D25D9AB5390Q42716227-0EB89E79-53B7-4FEF-AA32-D286439E6A70Q42725493-72DD8650-95AD-472A-BF37-3DA90D18A9EEQ42805902-D064A5B9-EAC9-45CF-A115-E68F04B8FC7EQ42807900-AAB2AC6D-4246-479C-AC67-E97CF7E2A177Q42813799-DCECE76D-3E68-476F-8A2D-4FD12A7F0A25Q42824016-83FD5B46-1A50-493F-BDA3-9A1F4FA0A035Q42826217-9180F564-0D5B-4F14-9B6C-AD45969FBAC0Q42826612-437CF7CA-110A-4D7E-AC2B-BFB7819F6D88
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Silvia Rivara
@ast
Silvia Rivara
@en
Silvia Rivara
@es
Silvia Rivara
@nl
Silvia Rivara
@sl
type
label
Silvia Rivara
@ast
Silvia Rivara
@en
Silvia Rivara
@es
Silvia Rivara
@nl
Silvia Rivara
@sl
prefLabel
Silvia Rivara
@ast
Silvia Rivara
@en
Silvia Rivara
@es
Silvia Rivara
@nl
Silvia Rivara
@sl
P1053
K-8104-2017
P106
P1153
35586245800
P21
P2456
P31
P3829
P496
0000-0001-8058-4250